![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 46, 32786-32794, November 12, 1999
,
From the Friedrich Miescher-Institut, C-Mannosylation is a unique form of
protein glycosylation, involving the C-glycosidic
attachment of a mannosyl residue to the indole moiety of Trp. In the
two examples found so far, human RNase 2 and interleukin-12, only the
first Trp in the recognition motif WXXW is specifically
C-mannosylated. To establish the generality of protein
C-mannosylation, and to learn more about its mechanism, the
terminal components of the human complement system (C6, C7, C8,and C9),
which contain multiple and complex recognition motifs, were examined.
Together with C5b they form the cytolytic agent, the membrane attack
complex. These are the first proteins that are
C-mannosylated on more than one Trp residue as follows: six in C6, four in C7, C8 The modification of proteins by covalent attachment of
carbohydrate is a common feature of both intra- and extracellular
proteins (1, 2). In particular proteins that contain N- or
O-linked oligosaccharides have been known for a relatively
long time (3, 4), and many examples are known (1). Recently, a new type of glycosylation has been discovered in human RNase 2, which differs fundamentally from N- and O-glycosylation with
respect to the protein carbohydrate linkage. It involves the
C-glycosidic attachment of an The terminal complement proteins C6, C7, C8, and C9 are attractive
candidates for studying protein C-mannosylation because of
the following: (i) they contain complex C-mannosylation
motifs (WXXWXXW) as part of their thrombospondin
type 1 repeats (TSR modules); (ii) they possess up to three TSR
modules; and (iii) they have a clearly defined physiological function
(see below). The latter is important, since so far a function for
C-mannosylation of Trp residues has not been established.
The complement, which forms a first line of defense against microbial
infections, can be activated by three different pathways as follows:
the alternative, the classical, and the mannose-binding lectin-mediated
pathway (13, 14). Each of these results in the formation of the
membrane attack complex (MAC), the actual lytic component of complement
(15). The assembly of MAC begins with the formation of C5b by C5
convertase at the target membrane, followed by the sequential addition
of the plasma proteins C6, C7, C8, and C9 (see Reaction 1).
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, and C8
, and two in C9. Thus, from the 113 Trp residues in the complete membrane attack complex, 50 were found to
undergo C-mannosylation. The other important finding is
that in C6, C7, C8, and C9 Trp residues without a second Trp (or
another aromatic residue) at the +3 position can be
C-mannosylated. This shows that they must contain an
additional C-mannosylation signal. Whether this is encoded
in the primary or tertiary structure is presently unknown. Finally, all
modified Trp residues are part of the highly conserved core of the
thrombospondin type 1 repeats present in these proteins. Since this
module has been found in a large number of other proteins, the results
suggest further candidates for C-mannosylation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-mannopyranosyl residue to
the C-2 atom of the tryptophan side chain (5-7)
(Scheme 1). This modification has been
shown to be catalyzed by a microsome-associated transferase, which
C-mannosylates the first Trp residue in the recognition
sequence -WXXW- (8, 9). The enzyme uses dolichylphosphate
mannose as the sugar donor, and its activity has been found in mammals,
birds, amphibians, and fish. Furthermore, it could also be detected in
most mouse organs that were examined (10, 11). In addition to the
widespread distribution of the C-mannosyltransferase, its
recognition motif, WXXW, has been found in over 300 secreted mammalian proteins (9). This strongly suggests that
C- mannosylation is a more common form of glycosylation
than indicated by the fact that only two C-mannosylated
proteins have been characterized so far, i.e. human RNase 2 (5, 6) and IL-121 (12). These
two proteins contain a single C-mannosylation motif of the
simple structure WXXW. To further our insight into the process of protein C-mannosylation, we examine here proteins
that contain multiple and more complex C-mannosylation
motifs.

View larger version (17K):
[in a new window]
Scheme 1.
Structure of
C2-
-mannosyltryptophan.
![]()
View larger version (5K):
[in a new window]
Reaction 1.
C5b-9n forms a trans-membrane channel, whose exact size can vary, depending on the value of n. The association process has been examined in detail both on natural as well as artificial membranes (16-19). The value of n for the complete MAC ranges from 12 to 18 with an average of approximately 16 (see Ref. 19 for a discussion), which yields a calculated mass of 1.4 × 106 Da.
Here we have examined the C-mannosylation of Trp residues in
the TSR modules of C6, C7, C8
, C8
, and C9 by analyzing peptides by ESIMS, Edman degradation, and NMR. It was found that
C-mannosylation can occur at 50 out of 113 Trp residues in
the MAC and that also Trp residues without a second Trp at position +3
can undergo this modification.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials-- Human complement component C6 was purchased from Sigma, and components C7, C8, and C9 were from Advanced Research Technologies, San Diego, CA. Component C9 used in the protein chemical analyses was a generous gift of Dr. J. Tschopp, University of Lausanne, Switzerland.
Protein Chemistry-- Proteins were reduced and carboxamidomethylated as described previously (20). Tryptic digestion of the proteins was performed twice in 50 mM Tris-HCl, pH 8.0, for 2 h at 37 °C at an enzyme to substrate ratio of 1/50 (C7 and C8) or 1/100 (C6 and C9). Subsequently, C7 and C8 were digested for 4 h with endoproteinase Asp-N (1/50; Roche Molecular Biochemicals) at 37 °C. The amount of protein per digest was 50-75 µg for C6, C7, and C8, and two digests were made. The total amount of C9 digested was 7 mg. Cleavage of isolated peptides with 200 ng of chymotrypsin was performed for 2 h at 37 °C.
Digests were fractionated by C8 reversed phase LC-ESIMS as described (10). If necessary final purification was achieved by LC-ESIMS, using 25 mM NH4 acetate, pH 6.0, containing 2 or 80% CH3CN, as buffers A and B, respectively.
Nanospray ESIMSMS and solid-phase Edman degradation were performed according to published methods (21, 22). The elution position of PTH-(C2-Man-)Trp was established by sequencing residues 5-10 of human RNase 2 (FT(C2-Man-)WAQW) (5) prior to analysis of each of the complement peptides.
NMR Spectroscopy--
NMR spectra were measured on a Varian
Unity Plus spectrometer operating at a 1H frequency of 600 MHz. Susceptibility matched NMR tubes (Shygemi) with sample volumes of
220 µl were used. Clean TOCSY spectra were recorded with a mixing
time of 40 and 80 ms. The spectra were folded once in
t1 to increase the resolution. The spectra were recorded with 192 increments and 160 transients. Experiments of samples
in 90% H2O, 10% D2O were recorded using the
Watergate method. Spectra were referenced against acetone (
= 2.225 ppm (23)).
Peptide Nomenclature--
The numbering of the mature protein
has been used here as follows: C6 (24), C7 (25), and C8
(26) as
corrected in Swiss-Prot entry P07357 and C8
(27) and C9 (28).
Tryptic peptides have been numbered according to their occurrence in
the mature polypeptide. Peptides that resulted from tryptic digestion
have been labeled with the prefix "T," whereas subsequent digestion with endoproteinase Asp-N and chymotrypsin have been indicated with the
affix "D" and "Ch," respectively.
In Vitro C-Mannosylation--
The peptide
Ac-WAKW-NH2, the C6-derived peptide
Ac-LLGDFGPWSDCD-NH2, and the C9-derived peptide
Ac-RMSPWSEWSQCD-NH2 were C-mannosylated in
vitro using salt-washed porcine liver microsomes as the source of
transferase (12). The reaction mixture contained in a total volume of
24 µl the following: 0.9 mM peptide, 22.5 pmol of
Dol-P-[2-3H]Man (5.6 Ci/mmol), porcine liver microsomes
(77 µg of protein), 20 mM Hepes-NaOH, pH 7.2, 0.2% (w/v)
Triton X-100, 2 µg/ml benzamidine, 5 µg/ml pepstatin, 5 µg/ml
leupeptin, 2 mM EGTA. The reaction was performed for 30 min
at 37 °C and stopped by the addition of 2 ml chloroform/methanol 3:2
(v/v) and 0.48 ml of water. After centrifugation the upper, aqueous,
phase contained the peptide. The radioactivity in 0.2 ml of the upper
phase was determined by scintillation counting (8). For preparative
purposes, 10 reactions were performed for 42 h at room temperature
(12). The radiolabeled peptide was reduced, carboxamidomethylated, and isolated by C18 reversed phase HPLC as described (5). Final purification was achieved after tryptic cleavage and fractionation by
C8 reversed phase LC-MS (12).
| |
RESULTS |
|---|
|
|
|---|
Component C9--
The fractionation of the tryptic peptides from
carboxamidomethylated C9 by reversed phase LC-ESIMS is shown in Fig.
1A. The MS data were extracted
for the theoretical mass of the peptide(s) containing a
C-mannosylation motif, with or without the mass of a hexosyl
residue (162 Da) added. Two forms of peptide T2, comprising residues
24-38 of the mature protein (for nomenclature of peptides and
numbering system see "Experimental Procedures"), were detected. Peptide T2-1, eluting at 41.1 min, had a molecular mass of 2101 Da
(Fig. 1B, upper panel), which was 162 Da heavier than
expected from the cDNA sequence (28, 29). This suggested the
presence of one hexosyl residue. ESIMSMS of this fraction yielded a
nearly complete series of y ions, confirming its sequence and
localizing the hexosyl residue to Trp-27 (Fig.
2A and Table
I). The spectrum showed secondary neutral
losses of 120 Da from [M+2H]2+ and y132+.
This fragmentation has typically been observed with aromatic C-glycosides (30, 31) and has previously been found with
(C2-Man-)Trp in RNase 2 (5) and IL-12 (12). Edman
degradation of this peptide yielded at the fourth cycle a
PTH-derivative that comigrated with PTH-(C2-Man-)Trp
obtained from human RNase 2 (Fig. 1C), a protein whose C-mannosylation has previously been extensively
characterized (5-7).
|
|
|
To confirm the identity of the mannosyl residue, the peptide was
analyzed by NMR spectroscopy. The region of the spectrum that is just
upfield from the water resonance is expected to be empty for a random
coil 15-mer peptide. It would only show signals of upfield shifted H
resonances in case the peptide would obtain stable turns or a
-sheet
structure. However, the amide resonances exchange very fast with
D2O, and the observed JHNH
couplings are all around the random coil value of 6-7 Hz, indicating
that the peptide was not structured (data not shown). This allows the unequivocal identification of anomeric sugar protons, which resonate in
this region. The anomeric part of the spectrum of the pentadecapeptide T2-1 is shown in Fig. 3B and
is compared with that of the C-mannosylated peptide isolated
from IL-12 (Fig. 3A (12)). It is evident from this
comparison that the doublet signal that resonates at 5.18 ppm and that
was split by a J coupling of 7.4 Hz is the anomeric H1'
resonance of (C2-Man-)Trp. This interpretation was
confirmed by the disappearance of one of the H2 resonances of Trp and
by the assignments of the other resonances of the sugar moiety and of
the Trp residue with the help of TOCSY experiments (Table
II). An additional doublet signal at 5.27 ppm which was split by a J coupling of 6.5 Hz was observed.
This signal has an intensity of only 15%. Minor components of the same
magnitude were also observed for the aromatic protons of
(C2-Man-)Trp. We therefore concluded that the extra
anomeric resonances were caused by the
cis-trans-isomerization of the peptide bond between Ser and
Pro preceding the mannosylated Trp (32), rather than by a heterogeneity
in the sugar moiety.
|
|
The identification of a second form of peptide T2 (T2-2 in Fig. 1A) was surprising, since its mass (2263 Da, Fig. 1B) indicated the presence of two hexosyl residues. However, the peptide only contained a single, simple C-mannosylation motif (-WSEW-). Its MS spectrum did not show the conspicuous loss of 162 Da which would indicate the presence of an O-linked hexose (Fig. 1B). In agreement with this, ESIMSMS demonstrated unequivocally that in this peptide Trp-27 and -30 were both C-hexosylated (Fig. 2B and Table I). The PTH-derivatives observed at cycles 4 and 7 during Edman degradation of this peptide comigrated exactly with each other and with PTH-(C2-Man-)Trp from RNase 2 (Fig. 1D).
The anomeric part of the 1H NMR spectrum of peptide T2-2 is shown in Fig. 3C. Interestingly, in comparison with sample T2-1, an additional doublet resonance was observed. The resonances at 5.20 and 5.18 ppm were split by J-couplings of 7.1 and 7.4 Hz, respectively. Fig. 3D shows part of the TOCSY spectrum, recorded with a mixing time of 80 ms. It is evident from this spectrum that these anomeric resonances are part of similar spin systems with approximately the same chemical shifts (Table II). In fact the TOCSY spectra are similar to those recorded of the peptides with only one glycosylated Trp. In the case of peptide T2-2 two indole H2 resonances were missing. Thus, it is concluded that in this particular case both Trp residues in the WXXW motif were C2-mannosylated. The signal at 5.27 ppm with an intensity of about 15%, caused by the cis-trans-isomerization of the Ser-Pro bond appeared in this spectrum as well.
Examination of the LC-ESIMS data did not reveal the presence of unmodified peptide T2. Furthermore, the other two Trp residues in component C9, at positions 176 and 436, were observed in the unmodified form only.
Component C8--
Component C8 is a heterotrimeric protein
consisting of a disulfide-linked
-
dimer and a non-covalently
associated
subunit. Both the
and
subunit contain two TSR
modules. To obtain peptides suitable for MS and sequence analysis,
carboxamidomethylated C8 was digested first with trypsin and
subsequently with endoproteinase Asp-N. Fractionation by reversed phase
LC-ESIMS yielded two C-glycosylated peptides originating
from the
-subunit,
T1-D (2155 Da; residues 1-26 with one hexosyl
residue) and
T57 (2317 Da; residues 508-522 with three hexosyl
residues). The fraction containing
T1-D was further cleaved with
chymotrypsin, yielding pure
T1-D-Ch (residues 10-18) upon LC-ESIMS
purification. Nanospray ESIMSMS of this peptide established that the
sugar moiety was attached to Trp-14, whereas Trp-17 occurred in the
unmodified form (Table I). The peptide was sequenced by Edman
degradation, showing exact comigration of the PTH-derivative at cycle 5 with PTH-(C2-Man-)Trp from RNase 2 (Table I).
Peptide
T57 contained three hexosyl residues and was purified to
apparent homogeneity by LC-ESIMS at pH 6.0 (data not shown). Its
nanospray ESIMSMS spectrum and Edman degradation (Table I) showed
unequivocally that Trp-512, -515, and -518 were
C-mannosylated. Consistent with this, no loss of 162 Da was
observed in MSMS experiments with either
T1-D-Ch or
T57, which
would have been evidence for O-linked hexosyl residues.
Since only C-mannosylated forms of
T1-D and
T57 were
detected in the chromatogram of the starting digest, it is concluded
that these four Trp residues were fully modified.
From the C8
chain two peptides,
T1-D (1942 Da, residues 10-22
with two hexosyl residues) and
T59 (2010 Da, residues 494-506 with
two hexosyl residues) were detected and purified further by LC-ESIMS at
pH 6.0 (data not shown). Both Trp-16 and -19 in
T1-D were modified,
as was demonstrated by nano-ESIMSMS, which showed a continuous series
of b and y ions covering both Trp residues, as well as 120-Da loss from
a number of ions (Table I). These results were confirmed by Edman
degradation (Table I). Peptide
T59 still contained a contaminating
peptide (YILNTR), even after rechromatography. Its presence did not,
however, interfere with further analysis. ESIMSMS localized the hexosyl
residues on Trp-497 and -500, and 120-Da losses were observed from the
parent as well as the y7 and y9 ions (Table I). Edman degradation
confirmed Trp-494 to be unmodified and yielded
PTH-(C2-Man-)Trp in cycles 4 and 7 (Table I). With neither
of these peptides was any evidence for O-linked hexosyl
residues obtained.
These results extend the unexpected finding in C9 that Trp residues without a Trp or another aromatic residue at position +3 can be C-mannosylated.
Component C7--
Of the two TSR modules in component C7 only the
second one contains WXXW motifs. Nevertheless, a
tryptic/Asp-N peptide from the first repeat was found that had a mass
that was 162 Da larger than expected from the cDNA sequence (T1-D,
1897 Da, residues 9-22). ESIMSMS of this peptide (Fig.
4A) positioned the substituent at Trp-14, and a C-glycosidic linkage was concluded from the
120-Da loss from the parent, the y10, and y11 ions. Further evidence was obtained by Edman degradation of the peptide that had been purified
by reversed phase LC-ESIMS at pH 6.0. The PTH-derivative produced in
cycle 6 comigrated with PTH-(C2-Man-)Trp from RNase 2 (Table I).
|
From the second repeat four different C-glycosylated peptides were obtained. Approximately equal amounts of unmodified peptide (T50-D-1, 3193 Da, residues 465-494) and mono-hexosylated peptide (T50-D-2, 3355 Da) were detected. A nearly complete y and b ion series in the ESIMSMS analysis of T50-D-1 confirmed its sequence and the absence of modification (Table I). Similarly, the spectrum of T50-D-2 confirmed the structure and established the site of modification at Trp-484, with 120-Da losses from the parent and the doubly charged y13, y17, and y23 and y24 ions (Table I). Two peptides containing two modified Trp residues were found as minor fractions, T50-D-3 and T50-D-4 with a mass of 3517 Da. ESIMSMS analysis established that in T50-D-3 Trp-481 and -484 were modified, whereas T50-D-4 contained modified Trp-484 and -487 (Table I). The amount of these two peptides was too small for further purification and analysis by Edman degradation.
Component C6-- C6 contains three TSRs, with WXXW motifs present in the first and third repeat (residues 8-11 and 547-553). In the second repeat a single Trp is present but no C-mannosylation motif. The C-mannosylation of Trp-14 in C7, however, warranted the analysis of this region of C6.
Fractionation of the tryptic digest of C6 yielded a variety of peptides that originated from the TSR modules. This complexity was caused by the partial modification of most Trp residues. Peptide T1 (residues 1-16) from the first repeat was detected in two chromatographically separated fractions. Each of these was digested with chymotrypsin and purified to apparent homogeneity by reversed phase LC-ESIMS. The ions observed in the collision-induced dissociation spectrum of T1-Ch-1 (853 Da; residues 7-11 containing 1 hexosyl residue) demonstrated Trp-8 to contain the hexosyl residue. Since the parent, and the b3 and b4 ions showed the typical 120 Da loss, the presence of a C-glycosidic linkage was concluded. These results were confirmed by Edman degradation (Table I). The ESIMSMS analysis of T1-Ch-2 (1578 Da, residues 7-16 containing 2 hexosyl residues) is shown in Fig. 4B. The spectrum illustrates the complexity that may arise due to the presence of more than one (C2-Man)-Trp residue. Loss of 120 Da, as well as multiple losses of H2O, were observed twice from the doubly charged parent ion. Furthermore, the data clearly show that both Trp-8 and -11 were modified with a hexosyl residue. Edman degradation confirmed the sequence of the peptide and provided chromatographic evidence for the presence of (C2-Man-)Trp at cycles 2 and 5 (Table I).
Peptide T8, which contains Trp-69 but no recognition motif, was detected mainly in the unmodified form (2653 Da, residues 57-78). Since the mass of this peptide as well as its ESIMSMS spectrum fully established its structure, no Edman degradation was carried out. The peptide with modified Trp-69 was a minor fraction. ESIMSMS of the unpurified chymotryptic fragment (T8-Ch, 2058 Da, residues 63-78) confirmed its identity and provided clear evidence for its C-hexosylation. The observations that its mass and that of the y11 and y12 ions was 162 Da higher than expected from the cDNA showed that Trp-69 contains the hexosyl residue (Table I). The loss of 120 Da typical for aromatic C-glycosides was observed for the parent, the y11, and y12 ions. Because the peptide was obtained in very low amounts and impure, no attempt was made to analyze it by Edman degradation.
Peptide T69, which contains Trp-547, -550, and -553, was detected in four separate chromatographic fractions. The major one contained modified Trp-547 and -550, as shown by ESIMSMS analysis and Edman degradation (Table I) of its purified chymotryptic fragment (T69-Ch, 1964 Da, residues 540-553). Minor amounts of T69 with Trp-550 and 553 (T69-2; 2890 Da) or all three Trp residues modified (T69-3, 3052 Da) were detected. The amount of these peptides did not allow further purification and characterization by Edman degradation. Nevertheless, their analysis by ESIMSMS was consistent with C-hexosylation as summarized in Table I.
A small amount of completely unmodified T69 was detected as well (T69-1, 2566 Da). Since its primary structure was fully established by ESIMSMS, no Edman degradation was done.
Component C6 contains six further Trp residues. The LC-ESIMS data of the first fractionation of the digest was extracted for the masses of each of the expected peptides assuming either the presence of Trp or (C2-Man-)Trp. All peptides were found in the unmodified form only.
A summary of the data obtained for all four terminal components,
including an estimate of the stoichiometry of modification, is
shown in Fig. 5.
|
In Vitro C-Mannosylation-- C-Mannosylation in human RNase 2 and IL-12 can be reproduced in vitro using peptides containing the motif WXXW and a microsome-associated transferase (8, 12). The modification in these cases is completely restricted to the first Trp, and replacement of the second by Ala completely abolishes the modification in vitro and in vivo (8, 9). In contrast, the results summarized in Fig. 5 show that all terminal components of complement contain one or more C-mannosylated Trp residues with a Cys rather than Trp or another aromatic residue at the +3 position. It was therefore of interest to examine the in vitro C-mannosylation of such peptides.
The peptide Ac-LLGDFGPWSDCD-NH2 derived from C6 and
Ac-RMSPWSEWSQCD-NH2 derived from C9 were incubated with
porcine liver microsomes and Dol-P-[2-3H]Man. The general
acceptor peptide Ac-WAKW-NH2 was used as a positive control
(12). As shown in Fig. 6A no
C-mannosylation could be detected in the peptide from C6,
whereas the one from C9 was nearly as effective an acceptor as the
control peptide. To determine the site(s) of modification the
radiolabeled C9 peptide was isolated from the reaction mixture by
C18 reversed phase HPLC (Fig. 6B). This yielded
a major peak of radioactivity eluting at 19.5 min which contained a
peptide with a mass expected for the mono-hexosylated peptide from C9
(1771 Da). The minor peak eluting at 18.5 min contained 8% of the
recovered radioactivity. ESIMSMS analysis demonstrated it to be the
same peptide, but with oxidized Met at position 2. The major peptide
was cleaved with trypsin to remove Ac-Arg and yielded a single
radioactive peak upon purification by rechromatography on a
C8 HPLC column (data not shown). The purified peptide had a
mass of 1574 Da, corresponding to
MSPWSEWSQ(carboxamidomethyl)CD-NH2 plus an additional
hexosyl residue. The ESIMSMS spectrum of this peptide is depicted in
Fig. 6C. The m/z values of the b4, b5, and b6
ions identified the first Trp residue as the attachment site of the
mannosyl residue. Furthermore, the values of the y5, y6, and y7 ions
provided evidence for the unmodified second Trp. Importantly, y ions at
m/z 856, 985, and 1072, which would have indicated
C-mannosylation of the second Trp, were conspicuously absent
in the spectrum (arrows in Fig. 6C). These
results were confirmed by Edman degradation of the radiolabeled
peptide. A peak of radioactivity was observed in the 4th cycle (the
position of the first Trp) but not in cycle 7 (data not shown). Thus,
in vitro C-mannosylation of the peptide from C9
was restricted to the first Trp in the WXXW motif.
|
| |
DISCUSSION |
|---|
|
|
|---|
The results presented here demonstrate that C-mannosylation of Trp residues is not a rare event restricted to RNase 2 and IL-12. Nearly all Trp residues in the TSR modules of the four terminal components of complement can be C-mannosylated (Fig. 5). The most complete analysis was carried out on component C9, where the presence of the (C2-Man-)Trp residues at positions 27 and 30 was established by MS, Edman degradation, and NMR. The identity of the hexosyl residue was established by comparing chemical shifts and J-coupling data of the peptides from C9 with those of peptides obtained from RNase 2 and IL-12. The close agreement of these parameters showed that the chemical structure of residues 27 and 30 of C9 is identical to that of (C2-Man-)Trp present in RNase 2 and IL-12 (5, 6, 12). No NMR data are available for C-linked hexoses other than mannose. However, they are expected to have significantly different chemical shifts, connectivity patterns, and coupling constants (6). For the other three terminal components, (C2-Man-)Trp in the major peptides (modified fraction >0.1 mol/mol, Table I) was established by MS and comigration of its PTH-derivative with PTH-(C2-Man-)Trp from human RNase 2. No further NMR analysis was done for these, because of lack of sufficient amounts of protein. Furthermore, we feel confident that the MS and Edman degradation studies are sufficiently supported by NMR in the past (5-7, 12) and by the analysis of C9 (this paper). Therefore, NMR is only required in unusual new cases. Exact comigration of the PTH-derivatives of the modified Trp residues with authentic PTH-(C2-Man-)Trp was always observed (Table I). Due to the lack of synthetic standards and natural examples, the elution position of PTH-(C2-hexose)-Trp with hexoses other than mannose has not been established. It seems unlikely, however, that these would comigrate with PTH-(C2-Man-)Trp. The small peak eluting shortly after the main peak of PTH-(C2-Man-)Trp (* in Fig. 1, C and D) is a diastereomer (5). The good separation between these peaks suggests that the resolution of the system is sufficient to separate other hexose derivatives as well. The recent publication of a synthetic route for (C2-Man-)Trp will possibly also lead to the synthesis of the other hexosyl derivatives and provide a solution to this matter (33).
In Fig. 5 an estimate of the stoichiometry of modification has been indicated. These values were calculated as a fraction of the total area of the [M + nH]n+ ions (n = 2 and 3) of a particular peptide in the original chromatogram of a digest. Differences in the efficiency of ionization of the differently modified forms of a peptide could affect the accuracy of intermediate values. The extreme values of 0 (no modified peptide found) and 1 (no unmodified peptide found) are unequivocal, however. Furthermore, in the case of C9 shown in Fig. 1A, where the two modified peptides were obtained in pure form from the original chromatogram, a good correlation between integration of the UV and MS data was observed.
C-Mannosylation is a significant feature of the MAC. The mature complex, C5b-C916 (19), has a calculated mass of approximately 1.4 × 106 Da and contains a total of 113 Trp residues. Of these, 50 have been found to undergo C-mannosylation. Taking into account the degree of modification of each of them, and assuming a random distribution in MAC particles, we calculated that on average a MAC contains 34 (C2-Man-)Trp residues. It has been hypothesized, but not proven, that the TSR modules in the complement proteins are involved in adhesion to each other and perhaps in the assembly of the MAC (34). Some support for this has been obtained from the inhibition of the assembly process by a monoclonal antibody specific for the third TSR module in C6 (35). Whether the (C2-Man-)Trp residues play a role in facilitating complex formation on the surface of the pathogen remains to be determined. Although interaction of (C2-Man-)Trp in the MAC with the multivalent mannose-binding lectin from serum has not been demonstrated yet, it could play a role, since this lectin has been shown to bind to a variety of microorganisms (for an overview see Ref. 14). Furthermore, many pathogenic microorganisms are known to carry mannose-binding proteins on their surface (36).
The C-mannosylation of the terminal components of complement reveals a number of novel features of protein C-mannosylation and the properties of TSR modules in general.
A new finding is that the TSR modules in the terminal complement components contain more than one modified Trp residue. Unexpectedly, Trp residues that do not have a Trp or another aromatic residue at the +3 position were found to be C-mannosylated. The most extreme examples being Trp-69 in C6 and Trp-14 in C7, which are not even part of a WXXW motif (Fig. 5). This is in contrast with human RNase 2 and IL-12 (5, 12). Reexamination of their LC-ESIMS data, in the light of these new findings, confirmed that in these proteins C-mannosylation takes place exclusively on the first Trp. The case of RNase 2 is particularly compelling, because it holds for the enzyme from urine and HL-60 cells (5, 10), as well as for recombinant RNase 2 and the hybrid RNase 2.4 from HEK-293 cells (9). Furthermore, in vitro studies with the microsome-associated transferase from liver and IL-12-secreting B-lymphoblastoid cells confirm these findings (12). The most likely explanation for the C-mannosylation of Trp residues that do not have a Trp or another aromatic residue at the +3 position is that the terminal complement components contain, in addition to the WXXW motif, another signal for C-mannosylation of these Trp residues. In all cases such Trp residues are part of the sequence W(S/T)XC (Fig. 5). If this sequence, or a segment of it, would form the recognition motif, it seems likely that another transferase than the one recognizing WXXW is involved. Support for this was provided by the in vitro C-mannosylation experiments (Fig. 6). No C-mannosylation of the peptide from C6 was observed, and C-mannosylation of the one from C9 was restricted to the first Trp residue. An alternative explanation would be that the extra signal is located outside this sequence or that it is formed by a three-dimensional "signal patch" akin to substrates for UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. These proteins contain a conformation-dependent protein determinant for interaction with the transferase that is formed by amino acid residues that are separated in the primary structure (37).
The data obtained here (Fig. 6), together with those obtained previously (5, 12), allow a partial definition of interspersing residues that are compatible with C-mannosylation of the WXXW motif. Whereas Thr, Ala, Gly, and Ser may occur at position +1, Cys, Ala, Asn, Ser, Glu, and Gln are allowed at position +2. Clearly, further studies are needed to complete this analysis.
There is no three-dimensional structure available for a TSR module, but the results presented here allow the definition of some of its spatial properties in the complement components. The hydrophilic nature of a mannosyl residue makes it unlikely that it is buried in the molecule. Consequently, the Trp residues that become C-mannosylated probably occur on the surface of the module. This proposal is consistent with the position of Trp-7 in the three-dimensional structure of recombinant human RNase 2 (38) and model building of the mannosyl residue (39). Furthermore, the occurrence of more than one (C2-Man-)Trp residue within a motif poses sterical restrictions on possible backbone conformations. Model building shows that in such a case the polypeptide chain cannot adopt a helical conformation like it does in RNase 2, which contains only a single (C2-Man-)Trp residue.
In addition to TSP-1 and the terminal components of complement, TSR modules have been found in a number of other proteins as follows: properdin (40), F-, M-, and SCO-spondin (41-44), semaphorin F and -G (45), brain-specific angiogenin inhibitor-1, -2, and -3 (46, 47), a disintegrin and metalloproteinase with thrombospondin repeat-1 (48), aggrecanase (49), UNC-5 (50), and thrombspondin-related anonymous protein (51). Since all of them contain at least one WXXW motif, it will be of interest to examine these proteins for C-mannosylation as well. TSR modules have been classified into three groups based on length, position of cysteine residues, and net charge (52). The terminal components contain examples of each of these groups, and the present results show that all of them can be C-mannosylated (Fig. 5). The exact function of the TSR module, and therefore that of (C2-Man-)Trp, remains unknown. By far the most information has been obtained for TSP-1. TSP is a modular cellular adhesion molecule that has been proposed to interact with a variety of cells and macromolecules (for an overview see Refs. 53 and 54). Its TSR modules, and more importantly the WXXW motif and the neighboring sequence CSVTC, have been implicated in the adhesive process with a number of cells (55) and in protein-protein (56-58) and protein-glycosaminoglycan interactions (59). It is of interest to note that C6, C7, C8, and C9, as well as most of the above-mentioned proteins, act at the cell surface through protein-protein and protein-membrane interaction.
The results obtained here may also bear upon proteins that are not related to TSP. One of the best conserved portions of the sequence of the TSR module, WSXWS (52), occurs in nearly all type 1 cytokine receptors (60). Their analysis for C-mannosylation would be of interest because mutagenesis studies have revealed the functional importance of this so-called "WSXWS box" (61, 62).
In conclusion, we have shown that C-mannosylation can occur
on multiple Trp residues in a protein. As exemplified by the membrane attack complex, this modification may alter a large proportion of the
Trp residues. The results further demonstrate that this post-translational modification is more widespread than initially seemed to be the case. In particular proteins that contain TSR modules,
and the class 1 cytokine receptors appear to be highly probable
candidates for C-mannosylation. New mechanistic insights were obtained by the discovery of C-mannosylation of Trp
residues outside or at the C-terminal end of WXXW
motifs. Finally, the C-mannosylation of four complement
proteins with clearly defined physiological roles provides the
structural basis for studies on the function of
(C2-Man-)Trp residues.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Jürg Tschopp, University of Lausanne, for the generous gift of component C9; Renate Matthies for amino acid sequencing; and Drs. Brian Hemmings and Jack Rohrer for reading the manuscript.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Friedrich
Miescher-Institut, P. O. Box 2543, CH-4002 Basel, Switzerland. Tel.: 41 61 697 4722; Fax: 41 61 697 3976; E-mail: hofsteen@fmi.ch.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: IL-12, interleukin 12; Dol-P-Man, dolichyl-phosphate-mannose; ESIMS, electrospray ionization MS; LC-ESIMS, high performance liquid chromatography interfaced with ESIMS; MAC, membrane attack complex; MS, mass spectrometry; PTH-, phenylthiohydantoin-; TSP, thrombospondin; TSR, TSP type 1 repeat; HPLC, high pressure liquid chromatography.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Lis, H., and Sharon, N. (1993) Eur. J. Biochem. 218, 1-27[Medline] [Order article via Infotrieve] |
| 2. | Hart, G. W. (1997) Annu. Rev. Biochem. 66, 315-335[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Gottschalk, A. (1966) in Glycoproteins (Gottschalk, A., ed) , pp. 1-19, Elsevier Publishing Company, Amsterdam |
| 4. | Gottschalk, A. (1966) in Glycoproteins (Gottschalk, A., ed) , pp. 273-295, Elsevier Publishing Company, Amsterdam |
| 5. | Hofsteenge, J., Müller, D. R., de Beer, T., Löffler, A., Richter, W. J., and Vliegenthart, J. F. G. (1994) Biochemistry 33, 13524-13530[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | de Beer, T., Vliegenthart, J. F. G., Löffler, A., and Hofsteenge, J. (1995) Biochemistry 34, 11785-11789[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Löffler, A., Doucey, M.-A., Jansson, A. M., Müller, D. R., de Beer, T., Hess, D., Meldal, M., Richter, W. J., Vliegenthart, J. F. G., and Hofsteenge, J. (1996) Biochemistry 35, 12005-12014[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Doucey, M.-A.,
Hess, D.,
Cacan, R.,
and Hofsteenge, J.
(1998)
Mol. Biol. Cell
9,
291-300 |
| 9. |
Krieg, J.,
Hartmann, S.,
Vicentini, A.,
Gläsner, W.,
Hess, D.,
and Hofsteenge, J.
(1998)
Mol. Biol. Cell
9,
301-309 |
| 10. |
Krieg, J.,
Gläsner, W.,
Vincentini, A.,
Doucey, M.-A.,
Löffler, A.,
Hess, D.,
and Hofsteenge, J.
(1997)
J. Biol. Chem.
272,
26687-26692 |
| 11. | Doucey, M.-A. (1998) Ph.D. Thesis , Université Louis Pasteur de Strassbourg |
| 12. |
Doucey, M.-A.,
Hess, D.,
Blommers, M. J.,
and Hofsteenge, J.
(1999)
Glycobiology
9,
435-441 |
| 13. | Müller-Eberhard, H. J. (1988) Annu. Rev. Biochem. 57, 321-347[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Turner, M. W. (1996) Immunol. Today 17, 532-540[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Müller-Eberhard, H. J. (1986) Annu. Rev. Immunol. 4, 503-528[Medline] [Order article via Infotrieve] |
| 16. | Tschopp, J., Müller-Eberhard, H. J., and Podack, E. R. (1982) Nature 298, 534-538[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Tschopp, J.,
Engel, A.,
and Podack, E. R.
(1984)
J. Biol. Chem.
259,
1922-1928 |
| 18. |
Tschopp, J.
(1984)
J. Biol. Chem.
259,
7857-7863 |
| 19. | Silversmith, R. E., and Nelsestuen, G. L. (1986) Biochemistry 25, 852-860[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Hofsteenge, J.,
Servis, C.,
and Stone, S. R.
(1991)
J. Biol. Chem.
266,
24198-24204 |
| 21. | Wilm, M., Shevchenko, A., Houthaeve, T., Breit, S., Schweigerer, L., Fotsis, T., and Mann, M. (1996) Nature 379, 466-469[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Pisano, A.,
Redmond, J. W.,
Williams, K. L.,
and Gooley, A. A.
(1993)
Glycobiology
3,
429-435 |
| 23. | Vliegenthart, J. F. G., Dorland, L., and van Halbeek, H. (1983) Adv. Carbohydr. Chem. Biochem. 41, 209-374 |
| 24. |
DiScipio, R. G.,
and Hugli, T. E.
(1989)
J. Biol. Chem.
264,
16197-16206 |
| 25. |
DiScipio, R. G.,
Chakravarti, D. N.,
Muller-Eberhard, H. J.,
and Fey, G. H.
(1988)
J. Biol. Chem.
263,
549-560 |
| 26. | Rao, A. G., Howard, O. M. Z., Ng, S. C., Whitehead, A. S., Colten, H. R., and Sodetz, J. M. (1987) Biochemistry 26, 3556-3564[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Haefliger, J.-A., Tschopp, J., Nardelli, D., Wahli, W., Kocher, H.-P., Tosi, M., and Stanley, K. K. (1987) Biochemistry 26, 3551-3556[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
DiScipio, R. G.,
Gehring, M. R.,
Podack, E. R.,
Kan, C. C.,
Hugli, T. E.,
and Fey, G. H.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
7298-7302 |
| 29. | Stanley, K. K., Kocher, H.-P., Luzio, J. P., Jackson, P., and Tschopp, J. (1985) EMBO J. 4, 375-382[Medline] [Order article via Infotrieve] |
| 30. | Li, Q. M., van den Heuvel, H., Dillen, L., and Claeys, M. (1992) Biol. Mass Spectrom. 21, 213-221 |
| 31. | Becchi, M., and Fraisse, D. (1989) Biomed. Environ. Mass Spectrom. 18, 122-130[CrossRef] |
| 32. | Gratwohl, C., and Wüthrich, K. (1976) Biopolymers 15, 2025-2041[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Nishikawa, T., Ishikawa, M., and Isobe, M. (1998) Syn. Lett. 1, 123-125 |
| 34. | Maves, K. K., and Weiler, J. M. (1993) Immunol. Res. 12, 233-243[Medline] [Order article via Infotrieve] |
| 35. | Wuerzner, R., Mewar, D., Fernie, B. A., Hobart, P., and Lachmann, P. J. (1995) Immunology 85, 214-219[Medline] [Order article via Infotrieve] |
| 36. | Sharon, N. (1986) in The Lectins: Properties, Functions, and Applications in Biology and Medicine (Liener, I. E. , Sharon, N. , and Goldstein, I. J., eds) , pp. 493-527, Academic Press, Inc., London |
| 37. |
Baranski, T. J.,
Koelsch, G.,
Hartsuck, J. A.,
and Kornfeld, S.
(1991)
J. Biol. Chem.
266,
23365-23372 |
| 38. | Mosimann, S. C., Newton, D. L., Youle, R. J., and James, M. N. G. (1996) J. Mol. Biol. 260, 540-552[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Vliegenthart, J. F. G., and Casset, F. (1998) Curr. Opin. Struct. Biol. 8, 565-571[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Goundis, D., and Reid, B. M. (1988) Nature 335, 82-85[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Klar, A., Baldassare, M., and Jessell, T. M. (1992) Cell 69, 95-110[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Higashijima, S., Nose, A., Eguchi, G., Hotta, Y., and Okamoto, H. (1997) Dev. Biol. 192, 211-227[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Umemiya, T., Takeichi, M., and Nose, A. (1997) Dev. Biol. 186, 165-176[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Gobron, S., Monnerie, H., Meiniel, R., Creveaux, I., Lehmann, W., Lamalle, D., Dastugue, B., and Meiniel, A. (1996) J. Cell Sci. 109, 1053-1061[Abstract] |
| 45. | Adams, R. H., Betz, H., and Püschel, A. W. (1996) Mech. Dev. 57, 33-45[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, K., Ono, M., Kuwano, M., Nakamura, Y., and Tokino, T. (1997) Oncogene 15, 2145-2150[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Shiratsuchi, T., Nishimori, H., Ichise, H., Nakamura, Y., and Tokino, T. (1997) Cytogenet. Cell Genet. 79, 103-108[Medline] [Order article via Infotrieve] |
| 48. |
Kuno, K.,
Kanada, N.,
Nakashima, E.,
Fujiki, F.,
Ichimura, F.,
and Matsushima, K.
(1997)
J. Biol. Chem.
272,
556-562 |
| 49. |
Tortorella, M. D.,
Burn, T. C.,
Pratta, M. A.,
Abbaszada, I.,
Hollis, J. M.,
Liu, R.,
Rosenfeld, S. A.,
Copeland, R. A.,
Decicco, C. P.,
Wynn, R.,
Rockwell, A.,
Yang, F.,
Duke, J. L.,
Solomon, K.,
George, H.,
Bruckner, R.,
Nagase, H.,
Itoh, Y.,
Ellis, D. M.,
Ross, H.,
Wiswall, B. H.,
Murphy, K.,
Hillman, M. C.,
Hollis, G. F.,
Newton, R. C.,
Magolda, R. L.,
Trazkos, J. M.,
and Arner, E. C.
(1999)
Science
284,
1664-1666 |
| 50. | Leung-Hagesteijn, C., Spence, A. M., Stern, B. D., Zhou, Y., Su, M.-W., Hegecock, E. W., and Culotti, J. G. (1992) Cell 71, 289-299[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Robson, K. J. H., Hall, J. R. S., Jennings, M. W., Harris, T. J. R., Marsh, K., Newbold, C. I., Tate, V. E., and Weatherall, D. J. (1988) Nature 335, 79-82[CrossRef][Medline] [Order article via Infotrieve] |
| 52. | Smith, K. S., Nolan, K. F., Reid, K. B. M., and Perkins, S. J. (1991) Biochemistry 30, 8000-8008[CrossRef][Medline] [Order article via Infotrieve] |
| 53. | Lahav, J. (1993) in Thrombospondin (Lahav, J., ed) , CRC Press, Inc., Boca Raton, FL |
| 54. | Adams, J., and Lawler, J. (1993) Curr. Biol. 3, 188-190[CrossRef][Medline] [Order article via Infotrieve] |
| 55. |
Prater, C. A.,
Plotkin, J.,
Jaye, D.,
and Frazier, W. A.
(1991)
J. Cell Biol.
112,
1031-1040 |
| 56. |
Wei-Xing, L.,
Howard, R. J.,
and Leung, L. K. L.
(1993)
J. Biol. Chem.
268,
16179-16184 |
| 57. |
Dawson, D. W.,
Pearce, F. A.,
Yhong, R.,
Silverstein, R. L.,
and Frayier, W. A.
(1997)
J. Cell Biol.
138,
707-717 |
| 58. |
Crombie, R. R.,
Silverstein, R. L.,
MacLow, C.,
Pearce, S. F. A.,
Nachman, R. L.,
and Laurence, J.
(1998)
J. Exp. Med.
187,
25-35 |
| 59. |
Guo, N.,
Krutzsch, H. C.,
Negre, E.,
Vogel, T.,
Blake, D. A.,
and Roberts, D. D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3040-3044 |
| 60. |
Bazan, J. F.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6934-6938 |
| 61. | Miyazaki, T., Maruyama, M., Yamada, G., Hatakeyama, M., and Taniguchi, T. (1991) EMBO J. 10, 3191-3197[Medline] [Order article via Infotrieve] |
| 62. |
Hilton, D. J.,
Watowich, S. S.,
Katz, L.,
and Lodish, H. F.
(1996)
J. Biol. Chem.
271,
4699-4708 |
This article has been cited by other articles:
![]() |
E. Muroi, S. Manabe, M. Ikezaki, Y. Urata, S. Sato, T. Kondo, Y. Ito, and Y. Ihara C-Mannosylated peptides derived from the thrombospondin type 1 repeat enhance lipopolysaccharide-induced signaling in macrophage-like RAW264.7 cells Glycobiology, September 1, 2007; 17(9): 1015 - 1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Julenius NetCGlyc 1.0: prediction of mammalian C-mannosylation sites Glycobiology, August 1, 2007; 17(8): 868 - 876. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Li, L. Cui, D. L. Rock, and J. Li Novel Glycosidic Linkage in Aedes aegypti Chorion Peroxidase: N-MANNOSYL TRYPTOPHAN J. Biol. Chem., November 18, 2005; 280(46): 38513 - 38521. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. V. Bocharov, D. M. Korzhnev, M. J. J. Blommers, T. Arvinte, V. Yu. Orekhov, M. Billeter, and A. S. Arseniev Dynamics-modulated Biological Activity of Transforming Growth Factor beta 3 J. Biol. Chem., November 22, 2002; 277(48): 46273 - |